G1 Therapeutics, Inc. (NASDAQ:GTHX)

About the company

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

104

$1.00M

Total Revenue

104

Employees

$818.52M

Market Capitalization

-6.24

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$M

Operating Margin (in %)

Total operating margin

$M

Net Margin (in %)

Total net margin

$M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Johnson & Johnson JNJ 377376.69 82729.00 6.06 21.99 20.75
Merck & Co., Inc. MRK 202149.48 48081.00 7.59 19.94 21.10
Pfizer Inc. PFE 194670.90 50660.00 2.95 12.32 31.17
Eli Lilly & Co. LLY 150432.66 23087.00 51.05 26.52 23.97
AbbVie, Inc. ABBV 146737.92 34057.00 -23.49 17.50 24.65
Bristol Myers Squibb Co. BMY 110414.38 31006.00 2.68 93.87 3.08
Repligen Corp. RGEN 6459.15 286.00 6.19 281.44 8.11
Reata Pharmaceuticals, Inc. RETA 4893.35 20.00 23.18 -15.74 -150.30
Nektar Therapeutics NKTR 4139.52 137.00 3.23 -9.01 -335.62
Biohaven Pharmaceutical Holding Co. Ltd. BHVN 3702.40 1.00 34.23 -5.66 None
Allakos, Inc. ALLK 3144.30 None 6.83 -33.62 None
Karuna Therapeutics, Inc. KRTX 2767.96 None 7.23 -68.24 None
ADC Therapeutics SA ADCT 2756.70 2.00 32.52 -23.63 None
Turning Point Therapeutics, Inc. TPTX 2316.60 None 6.97 -19.38 None
IGM Biosciences, Inc. IGMS 2244.09 None 9.89 -41.37 None
Apellis Pharmaceuticals, Inc. APLS 2175.36 None 9.61 -5.22 None
OPKO Health, Inc. OPK 2155.86 891.00 1.53 -7.37 -32.92
Ra Pharmaceuticals, Inc. RARX 2111.78 3.00 8.68 -20.78 -585.71
Springworks Therapeutics, Inc. SWTX 1743.65 None 5.66 -27.97 None
Principia Biopharma, Inc. PRNB 1568.00 30.00 5.58 -22.31 -242.01
Y-mAbs Therapeutics, Inc. YMAB 1551.78 None 9.51 -16.84 None
Zymeworks, Inc. ZYME 1514.94 26.00 3.14 -8.93 -629.37
Akcea Therapeutics, Inc. AKCA 1370.61 341.00 2.81 -48.72 -8.59
Kiniksa Pharmaceuticals Ltd. KNSA 1305.15 None 6.76 -10.79 None
Tricida, Inc. TCDA 1298.01 None 6.67 -6.15 None
Arcutis Biotherapeutics, Inc. ARQT 1184.37 None 5.05 -18.94 None
Odonate Therapeutics, Inc. ODT 1163.48 None 9.53 -10.34 None
Athenex, Inc. ATNX 1070.16 123.00 6.56 -9.94 -87.86
Phibro Animal Health Corp. PAHC 1068.87 818.00 5.40 28.97 4.49
Akero Therapeutics, Inc. AKRO 957.58 None 8.00 -18.87 None
Constellation Pharmaceuticals, Inc. CNST 927.36 None 3.86 -9.99 None
Oric Pharmaceuticals, Inc. ORIC 838.04 None -9.10 -27.71 None
G1 Therapeutics, Inc. GTHX 818.52 1.00 3.54 -6.24 None
Gossamer Bio, Inc. GOSS 802.76 None 3.26 -4.04 None
Phathom Pharmaceuticals, Inc. PHAT 789.50 None 4.38 -2.90 None
Aprea Therapeutics, Inc. APRE 768.60 None 6.80 -22.73 None
Krystal Biotech, Inc. KRYS 760.75 None 4.44 -36.68 None
Quanterix Corp. QTRX 752.76 60.00 6.64 -17.21 -71.52
Applied Therapeutics, Inc. APLT 729.30 None 4.71 -14.80 None
Provention Bio, Inc. PRVB 669.94 None 10.60 -15.13 None
Provention Bio, Inc. PRVB 651.88 None 10.31 -14.72 None
Keros Therapeutics, Inc. KROS 644.40 8.00 -29.11 -30.34 -285.35
Amneal Pharmaceuticals, Inc. AMRX 619.24 1679.00 4.26 -2.84 -11.85
Arcturus Therapeutics Holdings, Inc. ARCT 605.28 19.00 56.10 -21.76 -151.34
Oyster Point Pharma, Inc. OYST 596.40 None 5.99 -10.36 None
Mirum Pharmaceuticals, Inc. MIRM 503.75 None 3.28 -7.44 None
SIGA Technologies, Inc. SIGA 489.54 19.00 5.48 -24.87 -94.00
Imara, Inc. IMRA 483.82 None 4.67 -13.75 None
Satsuma Pharmaceuticals, Inc. STSA 463.25 None 4.56 -12.73 None
Biospecifics Technologies Corp. BSTC 436.94 40.00 3.55 18.69 61.80
DURECT Corp. DRRX 416.64 28.00 32.00 -17.23 -82.94
Fulcrum Therapeutics, Inc. FULC 410.55 1.00 6.92 -5.95 None
Crinetics Pharmaceuticals, Inc. CRNX 406.56 1.00 5.13 -6.97 -447.78
Ocular Therapeutix, Inc. OCUL 396.48 6.00 -48.59 -4.32 None
89bio, Inc. ETNB 386.40 None 4.77 -5.99 None
Relmada Therapeutics, Inc. RLMD 385.02 0.00 5.74 -32.17 -877.66
Kala Pharmaceuticals, Inc. KALA 380.16 6.00 4.16 -4.14 None
TCR2 Therapeutics, Inc. TCRR 373.20 None 2.55 -37.02 None
Osmotica Pharmaceuticals Plc OSMT 349.38 232.00 2.65 -1.27 -115.44
Ovid Therapeutics, Inc. OVID 323.55 None 7.65 -4.96 None
Urovant Sciences Ltd. UROV 315.00 None -5.59 -2.18 None
Aeglea Biotherapeutics, Inc. AGLE 298.98 4.00 9.44 -3.73 -523.27
HOOKIPA Pharma, Inc. HOOK 280.28 13.00 2.54 -6.20 -333.02
IDEAYA Biosciences, Inc. IDYA 274.60 None 4.17 -6.30 None
AMAG Pharmaceuticals, Inc. AMAG 273.70 321.00 1.05 -0.74 -115.05
Lannett Co., Inc. LCI 270.56 542.00 0.92 -8.90 -5.77
Verrica Pharmaceuticals, Inc. VRCA 257.50 None 4.70 -8.44 None
Spero Therapeutics, Inc. SPRO 254.03 12.00 3.34 -3.12 -656.72
Gritstone Oncology, Inc. GRTS 236.88 4.00 2.12 -2.27 None
Kaleido Biosciences, Inc. KLDO 234.00 None 8.30 -3.20 None
KalVista Pharmaceuticals, Inc. KALV 233.46 12.00 2.58 -7.21 -263.38
Veru, Inc. VERU 218.40 39.00 7.30 -22.40 -25.53
LogicBio Therapeutics, Inc. LOGC 191.36 1.00 5.78 -4.50 None
Galera Therapeutics, Inc. GRTX 180.25 None 3.37 -2.74 None
Liquidia Technologies, Inc. LQDA 171.38 8.00 10.12 -3.48 -602.17
Sutro Biopharma, Inc. STRO 171.12 41.00 3.25 -2.81 -148.06
Protara Therapeutics, Inc. TARA 168.06 None 2.53 -10.90 None
Avenue Therapeutics, Inc. ATXI 167.52 532.00 30.79 -11.51 26.69
Evolus, Inc. EOLS 164.40 45.00 2.95 -1.62 -217.51
Evelo Biosciences, Inc. EVLO 160.96 None 4.12 -1.84 None
Cyclerion Therapeutics, Inc. CYCN 156.60 6.00 1.97 -1.51 None
Tyme Technologies, Inc. TYME 148.35 None 8.60 -6.79 None
Harrow Health, Inc. HROW 137.28 51.00 8.80 -5.56 -47.54
Trevi Therapeutics, Inc. TRVI 137.07 None 2.91 -4.67 None
scPharmaceuticals, Inc. SCPH 136.04 119.00 3.48 -4.34 -27.05
Lyra Therapeutics, Inc. LYRA 133.32 1.00 -1.13 -7.99 -491.16
Aquestive Therapeutics, Inc. AQST 131.88 49.00 -7.60 -1.88 -139.64
PhaseBio Pharmaceuticals, Inc. PHAS 127.31 2.00 2.36 -2.66 None
Mustang Bio, Inc. MBIO 122.40 None 2.86 -2.49 None
NeuBase Therapeutics, Inc. NBSE 121.24 None 50.94 -2.71 None
TFF Pharmaceuticals, Inc. TFFP 117.61 None 4.55 -3.03 None
Immunic, Inc. IMUX 117.40 None 3.45 -53.36 None
Ayala Pharmaceuticals, Inc. AYLA 116.64 3.00 -2.75 -5.65 -679.19
Eton Pharmaceuticals, Inc. ETON 99.36 1.00 10.82 -4.97 None
Milestone Pharmaceuticals, Inc. MIST 93.00 None 0.92 -1.49 None
Checkpoint Therapeutics, Inc. CKPT 79.60 2.00 6.86 -3.43 -949.53
EyePoint Pharmaceuticals, Inc. EYPT 79.57 26.00 5.62 -1.62 -196.30
Clearside Biomedical, Inc. CLSD 79.54 6.00 10.21 -4.51 -293.61
Xeris Pharmaceuticals, Inc. XERS 78.12 4.00 3.87 -0.60 None
Corvus Pharmaceuticals, Inc. CRVS 75.40 None 1.21 -1.60 None
Baudax Bio, Inc. BXRX 72.00 None -1.96 -1.03 None
Navidea Biopharmaceuticals, Inc. NAVB 68.34 1.00 -50.25 -6.18 -65.13
BiomX, Inc. PHGE 65.45 None 1.72 -1.53 None
Assertio Therapeutics, Inc. ASRT 59.04 192.00 1.02 -0.36 -83.99
Genprex, Inc. GNPX 57.57 None 4.89 -4.21 None
Aridis Pharmaceuticals, Inc. ARDS 56.97 1.00 -23.44 -1.95 -851.00
Menlo Therapeutics, Inc. MNLO 52.49 2.00 4.41 -0.56 -483.51
Aerpio Pharmaceuticals, Inc. ARPO 51.66 20.00 1.56 -2.74 -51.58
Eyenovia, Inc. EYEN 45.60 None 4.60 -2.23 None
Edesa Biotech, Inc. EDSA 44.82 0.00 6.38 -0.47 -395.23
Moleculin Biotech, Inc. MBRX 42.69 None 3.71 -4.64 None
Akari Therapeutics Plc AKTX 36.18 None -33.50 -2.01 None
Oncternal Therapeutics, Inc. ONCT 35.75 3.00 4.58 -1.42 -225.89
Allena Pharmaceuticals, Inc. ALNA 35.42 None 4.67 -0.81 None
Mannatech, Inc. MTEX 34.08 156.00 1.44 7.68 3.45
AgeX Therapeutics, Inc. AGE 33.78 2.00 -44.45 -2.78 -658.11
CNS Pharmaceuticals, Inc. CNSP 33.12 None 5.75 -6.09 None
Citius Pharmaceuticals, Inc. CTXR 32.94 None 2.44 -1.91 None
Acer Therapeutics, Inc. ACER 32.50 3.00 2.37 -1.25 -274.69
Aileron Therapeutics, Inc. ALRN 32.48 None 4.46 -1.22 None
Adamis Pharmaceuticals Corp. ADMP 31.32 22.00 1.20 -1.06 -140.33
Annovis Bio, Inc. ANVS 30.10 None 2.76 -23.89 None
Millendo Therapeutics, Inc. MLND 25.80 0.00 0.61 -0.55 None
Hoth Therapeutics, Inc. HOTH 25.00 None 6.94 -2.78 None
Spring Bank Pharmaceuticals, Inc. SBPH 23.20 0.00 0.88 -0.89 None
Akorn, Inc. AKRX 22.68 721.00 -1.20 -0.06 -55.64
Daré Bioscience, Inc. DARE 18.96 1.00 8.31 -1.13 None
ProPhase Labs, Inc. PRPH 16.80 9.00 1.52 -5.60 -31.15
Teligent, Inc. TLGT 14.40 60.00 -0.49 -0.36 -71.80
Teligent, Inc. TLGT 14.40 60.00 -0.49 -0.36 -71.80
Novan, Inc. NOVN 14.21 5.00 -3.27 -0.45 -602.34
Adial Pharmaceuticals, Inc. ADIL 13.80 None 3.37 -1.82 None
Titan Pharmaceuticals, Inc. TTNP 12.00 4.00 5.00 -0.67 -437.91
PDS Biotechnology Corp. PDSB 11.69 None 1.29 -0.46 None
Novus Therapeutics, Inc. NVUS 7.39 None 0.63 -0.35 None
Brickell Biotech, Inc. BBI 5.05 5.00 1.66 -0.07 -432.19
BioStar Pharmaceuticals, Inc. BSPM 0.21 0.00 0.01 0.10 294.01

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Were Hedge Funds Right About Betting On G1 Therapeutics, Inc. (GTHX)?

3d ago, source: YAHOO!

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds ...

G1 Therapeutics (NASDAQ:GTHX) Earns “Buy” Rating from Needham & Company LLC

2h ago, source: modernreaders.com

Needham & Company LLC reaffirmed their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a report released on ...

Brokers Issue Forecasts for G1 Therapeutics Inc’s Q3 2021 Earnings (NASDAQ:GTHX)

10h ago, source: modernreaders.com

Stock analysts at Wedbush issued their Q3 2021 earnings estimates for shares of G1 Therapeutics in a research note issued on ...

G1 Therapeutics Has Multiple Roadmaps To A Multi-Billion Dollar Market Cap

Opinion ago, source: Seeking Alpha

GTHX should submit an NDA for its Trilaciclib that, if approved, could generate $500MM-$1Billion in revenues/year in ...

BRIEF-G1 Therapeutics And Boehringer Ingelheim Announce Co-Promotion Agreement For Trilaciclib In Small Cell Lung Cancer In The U.S. And Puerto Rico

3d ago, source: Reuters

G1 THERAPEUTICS AND BOEHRINGER INGELHEIM ANNOUNCE CO-PROMOTION AGREEMENT FOR TRILACICLIB IN SMALL CELL LUNG CANCER IN THE UNITED STATES ...

BRIEF-G1 Therapeutics And Genor Biopharma Announce Exclusive License Deal For Lerociclib In Asia-Pacific Region

11d ago, source: Reuters

G1 THERAPEUTICS AND GENOR BIOPHARMA ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR LEROCICLIB IN ASIA-PACIFIC REGION * G1 THERAPEUTICS INC - G ...

Analyst: G1 Minimizes the Carnage of Chemotherapy

3d ago, source: streetwisereports.com

In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy rating and a $55 per share price target. The ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.